{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:34:02Z","timestamp":1773178442930,"version":"3.50.1"},"reference-count":5,"publisher":"Journal of Biomedical Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2025]]},"DOI":"10.7555\/jbr.38.20240107","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T20:53:13Z","timestamp":1723841593000},"page":"317","source":"Crossref","is-referenced-by-count":2,"title":["Therapy outcomes of IL-17 and JAK inhibitors in rosacea: A systematic review"],"prefix":"10.7555","volume":"39","author":[{"given":"Xinyi","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxingyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.38.20240107.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1\/Th17 pathways[J]. <i>J Invest Dermatol<\/i>, 2015, 135(9): 2198\u20132208.","DOI":"10.1038\/jid.2015.141"},{"key":"10.7555\/JBR.38.20240107.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Chen C, Wang P, Zhang L, et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: previous understanding and updates[J]. <i>Biomedicines<\/i>, 2023, 11(8): 2153.","DOI":"10.3390\/biomedicines11082153"},{"key":"10.7555\/JBR.38.20240107.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Fisher GW, Travers JB, Rohan CA. Rosacea pathogenesis and therapeutics: current treatments and a look at future targets[J]. <i>Front Med<\/i>, 2023, 10: 1292722.","DOI":"10.3389\/fmed.2023.1292722"},{"key":"10.7555\/JBR.38.20240107.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity <i>in vitro<\/i> and in a model of psoriasis[J]. <i>Br J Pharmacol<\/i>, 2010, 159(4): 842\u2013855.","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"key":"10.7555\/JBR.38.20240107.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Asena L, Akova YA, Cetinkaya A, et al. The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization[J]. <i>Acta Ophthalmol<\/i>, 2012, 91(3): e246\u2013e248.","DOI":"10.1111\/j.1755-3768.2012.02540.x"}],"container-title":["Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:36:18Z","timestamp":1769664978000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.38.20240107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"alternative-id":["JBR-2024-0107"],"URL":"https:\/\/doi.org\/10.7555\/jbr.38.20240107","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}